Q-omics provides the consensus-scored SCDP1 profile across patient tissues and cancer cell-line models. SCDP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SCDP1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SCDP1 RNA expression shows 13,526 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where SCDP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCDP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCDP1 survival associations across molecular data types. SCDP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCDP1 RNA expression–survival associations across cancer types. High SCDP1 expression shows unfavorable associations in BLCA, MESO, PAAD, ACC, KICH and DLBC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SCDP1 RNA expression.
This table summarizes SCDP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCDP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCDP1 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, UCEC, BLCA and HNSC. The KIRC box plot shows higher SCDP1 RNA expression in tumor versus normal tissue (log2 FC = +0.179, t-test p < 0.001).
This table shows molecular features associated with SCDP1 in patient tissues and cancer cell lines. In patient samples, SCDP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
